Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis C | 9 | 2024 | 238 | 3.030 |
Why?
|
| HIV Infections | 20 | 2025 | 2720 | 2.100 |
Why?
|
| Mass Screening | 9 | 2024 | 1149 | 1.880 |
Why?
|
| Pre-Exposure Prophylaxis | 6 | 2025 | 203 | 1.390 |
Why?
|
| Anti-HIV Agents | 6 | 2025 | 754 | 1.350 |
Why?
|
| Hepacivirus | 7 | 2024 | 235 | 1.220 |
Why?
|
| Drug Users | 1 | 2024 | 41 | 0.860 |
Why?
|
| Substance Abuse Treatment Centers | 1 | 2020 | 40 | 0.680 |
Why?
|
| Tenofovir | 2 | 2020 | 231 | 0.660 |
Why?
|
| Emtricitabine | 1 | 2020 | 168 | 0.640 |
Why?
|
| Emergency Service, Hospital | 8 | 2024 | 1902 | 0.550 |
Why?
|
| Continuity of Patient Care | 2 | 2019 | 275 | 0.510 |
Why?
|
| Coinfection | 2 | 2021 | 131 | 0.510 |
Why?
|
| HIV | 3 | 2022 | 226 | 0.500 |
Why?
|
| Choice Behavior | 1 | 2016 | 165 | 0.450 |
Why?
|
| Patient Preference | 1 | 2016 | 185 | 0.430 |
Why?
|
| Opioid-Related Disorders | 1 | 2020 | 484 | 0.410 |
Why?
|
| Viral Load | 1 | 2014 | 448 | 0.390 |
Why?
|
| Fasciola hepatica | 1 | 2012 | 5 | 0.390 |
Why?
|
| Topography, Medical | 1 | 2012 | 11 | 0.390 |
Why?
|
| Anti-Retroviral Agents | 1 | 2014 | 231 | 0.390 |
Why?
|
| Fascioliasis | 1 | 2012 | 6 | 0.390 |
Why?
|
| Syphilis | 2 | 2024 | 32 | 0.380 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2024 | 759 | 0.360 |
Why?
|
| Patient Compliance | 1 | 2014 | 565 | 0.340 |
Why?
|
| Humans | 33 | 2025 | 129650 | 0.320 |
Why?
|
| Adult | 18 | 2024 | 35576 | 0.310 |
Why?
|
| RNA, Viral | 2 | 2022 | 619 | 0.290 |
Why?
|
| Middle Aged | 15 | 2024 | 31154 | 0.270 |
Why?
|
| Colorado | 4 | 2024 | 4421 | 0.270 |
Why?
|
| Male | 21 | 2024 | 63681 | 0.250 |
Why?
|
| Hospitalization | 3 | 2024 | 2070 | 0.240 |
Why?
|
| Prevalence | 2 | 2022 | 2564 | 0.230 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2024 | 62 | 0.230 |
Why?
|
| Prospective Studies | 5 | 2025 | 7133 | 0.230 |
Why?
|
| HIV-1 | 3 | 2021 | 836 | 0.230 |
Why?
|
| Female | 19 | 2024 | 68776 | 0.220 |
Why?
|
| Mycoplasma genitalium | 1 | 2023 | 2 | 0.220 |
Why?
|
| Urethritis | 1 | 2023 | 3 | 0.220 |
Why?
|
| Proctitis | 1 | 2023 | 6 | 0.220 |
Why?
|
| Mycoplasma Infections | 1 | 2023 | 15 | 0.220 |
Why?
|
| Uterine Cervicitis | 1 | 2023 | 7 | 0.220 |
Why?
|
| Pelvic Inflammatory Disease | 1 | 2023 | 10 | 0.210 |
Why?
|
| Trench Fever | 1 | 2022 | 5 | 0.200 |
Why?
|
| Bartonella quintana | 1 | 2022 | 5 | 0.200 |
Why?
|
| Sexual Health | 1 | 2024 | 54 | 0.200 |
Why?
|
| Endocarditis | 1 | 2022 | 37 | 0.190 |
Why?
|
| Homosexuality, Male | 2 | 2021 | 175 | 0.180 |
Why?
|
| Housing | 1 | 2022 | 130 | 0.180 |
Why?
|
| Cost-Benefit Analysis | 1 | 2024 | 569 | 0.180 |
Why?
|
| Focus Groups | 1 | 2024 | 453 | 0.180 |
Why?
|
| Particulate Matter | 1 | 2023 | 246 | 0.180 |
Why?
|
| Patient Selection | 1 | 2024 | 663 | 0.180 |
Why?
|
| Safe Sex | 1 | 2020 | 21 | 0.180 |
Why?
|
| Health Services Accessibility | 2 | 2024 | 902 | 0.170 |
Why?
|
| Health Plan Implementation | 1 | 2020 | 137 | 0.160 |
Why?
|
| Community Health Centers | 1 | 2019 | 57 | 0.160 |
Why?
|
| Syphilis Serodiagnosis | 1 | 2019 | 4 | 0.160 |
Why?
|
| Treponema pallidum | 1 | 2019 | 8 | 0.160 |
Why?
|
| Hospitals | 1 | 2024 | 637 | 0.160 |
Why?
|
| Darunavir | 1 | 2019 | 18 | 0.150 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2019 | 31 | 0.150 |
Why?
|
| HIV Protease Inhibitors | 1 | 2019 | 68 | 0.150 |
Why?
|
| Drug Prescriptions | 1 | 2020 | 248 | 0.150 |
Why?
|
| United States | 6 | 2025 | 13903 | 0.150 |
Why?
|
| Administration, Oral | 1 | 2020 | 786 | 0.150 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2019 | 69 | 0.140 |
Why?
|
| Public Health Surveillance | 1 | 2018 | 68 | 0.140 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2020 | 248 | 0.140 |
Why?
|
| Qualitative Research | 1 | 2024 | 1235 | 0.140 |
Why?
|
| Time-to-Treatment | 1 | 2019 | 180 | 0.140 |
Why?
|
| Electronic Health Records | 1 | 2024 | 975 | 0.140 |
Why?
|
| Reproductive Health | 1 | 2018 | 86 | 0.130 |
Why?
|
| Treatment Outcome | 3 | 2023 | 10230 | 0.130 |
Why?
|
| Attitude of Health Personnel | 1 | 2024 | 1098 | 0.130 |
Why?
|
| Antibodies, Viral | 1 | 2020 | 601 | 0.130 |
Why?
|
| Program Evaluation | 1 | 2020 | 875 | 0.130 |
Why?
|
| Ribavirin | 1 | 2016 | 91 | 0.120 |
Why?
|
| Sexual and Gender Minorities | 1 | 2019 | 194 | 0.120 |
Why?
|
| Hepatitis C, Chronic | 1 | 2016 | 153 | 0.110 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 4897 | 0.110 |
Why?
|
| Algorithms | 1 | 2021 | 1622 | 0.110 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2014 | 266 | 0.110 |
Why?
|
| Primary Health Care | 2 | 2023 | 1680 | 0.100 |
Why?
|
| Medication Adherence | 1 | 2018 | 558 | 0.100 |
Why?
|
| Risk Factors | 4 | 2024 | 9765 | 0.100 |
Why?
|
| Referral and Consultation | 1 | 2018 | 732 | 0.100 |
Why?
|
| Cohort Studies | 2 | 2019 | 5420 | 0.100 |
Why?
|
| Delivery of Health Care | 2 | 2021 | 894 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 833 | 0.100 |
Why?
|
| Life Cycle Stages | 1 | 2012 | 36 | 0.100 |
Why?
|
| Africa | 1 | 2012 | 99 | 0.090 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 1266 | 0.090 |
Why?
|
| Retrospective Studies | 5 | 2025 | 14518 | 0.090 |
Why?
|
| Population Surveillance | 1 | 2014 | 439 | 0.090 |
Why?
|
| Travel | 1 | 2012 | 122 | 0.090 |
Why?
|
| Sofosbuvir | 2 | 2022 | 58 | 0.090 |
Why?
|
| Antiviral Agents | 1 | 2016 | 712 | 0.090 |
Why?
|
| Adolescent | 4 | 2024 | 20393 | 0.080 |
Why?
|
| Sexual Partners | 2 | 2024 | 185 | 0.080 |
Why?
|
| Socioeconomic Factors | 1 | 2014 | 1214 | 0.080 |
Why?
|
| Young Adult | 5 | 2024 | 12426 | 0.070 |
Why?
|
| Aged | 2 | 2019 | 22103 | 0.070 |
Why?
|
| Sensitivity and Specificity | 2 | 2021 | 1838 | 0.060 |
Why?
|
| Organizational Case Studies | 1 | 2025 | 75 | 0.060 |
Why?
|
| New Orleans | 1 | 2024 | 14 | 0.060 |
Why?
|
| Demography | 1 | 2024 | 279 | 0.050 |
Why?
|
| Time Factors | 1 | 2014 | 6556 | 0.050 |
Why?
|
| Macrolides | 1 | 2023 | 63 | 0.050 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2023 | 176 | 0.050 |
Why?
|
| Polyphosphates | 1 | 2022 | 37 | 0.050 |
Why?
|
| Pregnancy | 2 | 2024 | 6402 | 0.050 |
Why?
|
| Dried Blood Spot Testing | 1 | 2022 | 94 | 0.050 |
Why?
|
| Intention to Treat Analysis | 1 | 2021 | 68 | 0.050 |
Why?
|
| Nasopharynx | 1 | 2021 | 67 | 0.040 |
Why?
|
| Community-Based Participatory Research | 1 | 2022 | 148 | 0.040 |
Why?
|
| Fluorenes | 1 | 2020 | 40 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 5066 | 0.040 |
Why?
|
| Specimen Handling | 1 | 2021 | 164 | 0.040 |
Why?
|
| Alanine | 1 | 2020 | 142 | 0.040 |
Why?
|
| Protease Inhibitors | 1 | 2020 | 106 | 0.040 |
Why?
|
| Saliva | 1 | 2021 | 209 | 0.040 |
Why?
|
| Benzimidazoles | 1 | 2020 | 162 | 0.040 |
Why?
|
| Reagins | 1 | 2019 | 1 | 0.040 |
Why?
|
| Oxazines | 1 | 2019 | 28 | 0.040 |
Why?
|
| Adenine | 1 | 2020 | 256 | 0.040 |
Why?
|
| Research Design | 1 | 2024 | 1044 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2021 | 1023 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2022 | 847 | 0.040 |
Why?
|
| Chicago | 1 | 2018 | 57 | 0.040 |
Why?
|
| Pyridones | 1 | 2019 | 159 | 0.030 |
Why?
|
| Logistic Models | 1 | 2021 | 1988 | 0.030 |
Why?
|
| Piperazines | 1 | 2019 | 342 | 0.030 |
Why?
|
| Community Health Services | 1 | 2018 | 227 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 1040 | 0.030 |
Why?
|
| Physicians | 1 | 2024 | 865 | 0.030 |
Why?
|
| Animals | 2 | 2021 | 35361 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2019 | 1587 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2023 | 1717 | 0.030 |
Why?
|
| Child | 1 | 2019 | 20883 | 0.010 |
Why?
|